Cardinal Health Eyes Q2 Growth as Specialty Services Drive Outlook

Revenue for the pharmaceutical and medical supply distributor is forecast to hit $65.08 billion, a substantial jump from the $55.26 billion reported in the same period last year. Adjusted earnings are anticipated to reach $2.34 per share, reflecting the company’s improved operational efficiency. This momentum follows a recent upward revision of Cardinal Health's full-year outlook, with CEO Jason Hollar now targeting at least $10 per share in adjusted earnings.

The Specialty Growth Engine

The company’s specialty-solutions segment remains the primary catalyst for long-term expansion. Unlike traditional distribution, this unit focuses on high-margin, service-based revenue that has maintained organic growth in the mid-teens for several years. Recent acquisitions, including GI Alliance and Solaris Health, have further fortified this segment, allowing Cardinal Health to capture more value within the healthcare supply chain.

While weight-loss and diabetes treatments like GLP-1 medications have significantly boosted top-line revenue—contributing roughly six percentage points to the pharmaceutical segment's growth last quarter—their impact on the bottom line remains limited. Management has noted that these drugs carry thinner margins compared to specialty services. Investors will be watching closely to see if the company can convert this high-volume demand into sustainable profit growth while maintaining its 6.6% stock price gain seen over the past three months.